02251 AIRDOC-B
- 16.720
- -0.120-0.71%
AIRDOC-B News
鷹瞳科技-B：2023年年度報告
Eagle Hitomi Technology-B subsidiary plans to invest in partnership with Wenzhou Lufeng and Minsheng Equity Fund
Eagle Hitomi Technology-B (02251) announced that on April 16, 2024, Shanghai Zhongyou (a wholly-owned subsidiary of the company) signed a partnership agreement with Wenzhou Lufeng and Minsheng Equity Fund to establish a partnership. The total capital pledged by all partners under the partnership agreement is RMB 500 million, of which Shanghai Zhongyou promised to invest RMB 250 million. According to reports, the name of the partnership is Wenzhou Luming Private Equity Fund Management Partnership (Limited Partnership). Partnerships should make equity or other forms of investment permitted by applicable law, mainly for life sciences, healthcare services, smart healthcare, and artificial intelligence
Eagle Hitomi Technology-B (02251.HK) signs partnership agreement with Wenzhou Lufeng and Minsheng Equity Fund
Gelonghui, April 16, 丨 Eagle Eye Technology-B (02251.HK) announced that on April 16, 2024, Shanghai Zhongyou (a wholly-owned subsidiary of the company) signed a partnership agreement with Wenzhou Lufeng and Minsheng Equity Fund to establish a partnership. The total capital pledged by all partners under the partnership agreement is RMB 500 million, of which Shanghai Zhongyou promised to invest RMB 250 million. Partnerships shall make equity or other forms of investment permitted by applicable law, mainly in the fields of life sciences, healthcare services, smart medicine, and artificial intelligence. Since the company focuses on using artificial intelligence technology, it is slow
At a Glance | Airdoc (02251.HK) 2023 Annual Results
On March 27, 2023, Airdoc (2251.HK) announced its 2023 annual results.The company's revenue increased by 79.5% year-on-year, and gross profit increased by 124% year-on-year, achieving both revenue and
Eagle Hitomi Technology (2251.HK): Commercialization accelerates, AI medical imaging leader will reach an inflection point in performance
Technology is changing the world, and the application of AI technology may accelerate the arrival of the grand vision of “changing the world.” Recently, the “Godfather of AI” Hwang In-hoon declared in various public forums that “AI+ medical systems/biology” is the next shocking revolution to be ushered in in the field of technology. “The future of life science will be as highly engineered as traditional industries. When data science, artificial intelligence, and automation are combined, biology will improve exponentially, making it the next golden track.” This statement not only set off a boom in artificial intelligence and AI medicine in the capital market, but also made investors set their sights on those already looking ahead in this field
Understand the highlights of the 2023 annual results of Eagle Hitomi Technology (2251.HK) in one picture
On March 27, Eagle Eye Technology (2251.HK, Airdoc) announced the 2023 annual results report. Let me take you to understand the specific results in a picture.
Eagle Hitomi Technology-B (02251) announces 2023 annual results with revenue of 204 million yuan, up 79.46% year-on-year
Eagle Hitomi Technology-B (02251) announced results for the year ended December 31, 2023. The group achieved...
AIRDOC-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
AIRDOC-B: DATE OF BOARD MEETING
Changes in Hong Kong stocks | Eagle Hitomi Tech-B (02251) rose more than 6%, and Tomasz Jakub Mialkos recently increased its holdings by 55,000 shares
Eagle Hitomi Technology-B (02251) rose more than 6%. As of press release, it was up 6.12% to HK$13.52, with a turnover of HK$1,9541 million.
Research notes: AI retinal imaging pioneer, Eagle Hitomi Technology (2251.HK) has accumulated positive and weak results
Multiple uncertainties have accumulated in the current internal and external environment, and the market is facing a situation where sediment has concentrated. Comparatively speaking, AI tracks still radiate hope from time to time, and are equipped with certain safety pads. Based on humans' relentless pursuit of health, AI+ healthcare has spawned endless possibilities. Combined with the accelerated aging of the population, the field of early detection of chronic diseases is receiving more and more attention, and the pioneers on the racetrack are bound to rise to prominence at an accelerated pace.
Eagle Hitomi Technology-B (02251): The trustee purchased a total of 436,200 H shares under the 2022 equity incentive plan
According to the Zhitong Finance App, Eagle Eye Technology-B (02251) issued an announcement. In order to meet the relevant grants, from December 15, 2023 and until the date of this announcement, the trustee has further purchased a total of 436,200 H shares on the open market in accordance with the company's instructions, with an average daily transaction price of HK$10.76 to HK$11.14. The purchase of shares is disbursed from idle funds obtained from sales activities in the course of the Group's daily business.
Eagle Hitomi Technology-B (02251.HK): AirDoc-aifundus (1.0) obtained CE certification under the Medical Devices Regulations
Gelonghui, January 8 | Eagle Eye Technology-B (02251.HK) announced that the Group's AirDoc-aifundus (1.0) recently obtained the CE Mark (CE MDR) under the Medical Device Regulations. This mark allows full entry into 27 EU countries, including Belgium, Germany, Italy, France, etc. In addition to obtaining CE MDR, the Group's AirDoc-aifundus (1.0) and AI-FUNDUSCAMERA-P have also been successfully supervised by various international market-related agencies in Southeast Asia, the Middle East and Africa in the past two years
Eagle Eye Technology-B: The trustee recently purchased a total of 787,700 H shares under the 2022 equity incentive plan
Eagle Eye Technology-B (02251) announced that from September 18, 2023 and until the date of this announcement, trustees have purchased a total of 787,700 H shares on the open market, with an average daily transaction price of about HK$10.17 to HK$11.94. The purchase of shares is disbursed from idle funds obtained from sales activities in the course of the Group's daily business.
Eagle Eye Technology-B (02251): The trustee recently purchased a total of 787,700 H shares under the 2022 equity incentive plan
Eagle Eye Technology-B (02251) issued an announcement. Starting from September 18, 2023 and until the date of this announcement, the trust...
Eagle Hitomi Technology-B (02251.HK) proposes to grant repurchase authorization
Glonghui November 24 | Yingpupi Technology-B (02251.HK) announced that on November 24, 2023, the board of directors resolved to recommend the grant of repurchase authorization for shareholders to approve at the special shareholders' meeting. After shareholders have approved the repurchase authorization at the special shareholders' meeting and the relevant category of shareholders' meetings, and in accordance with the terms therein, the company may be allowed to repurchase up to 5,341,700 H shares, accounting for 10% of the total face value of H shares issued on the day the resolution approving the repurchase authorization was passed. It is assumed that the company will not issue shares from the date of this announcement and until the date of the special shareholders' meeting. The director believes that the repurchase authorization is in line with the public
Eight high-level papers from Takamitomi Technology (2251.HK) were selected for MICCAI 2023
On October 8-12, MICCAI 2023, internationally recognized as the most influential academic conference in the field of medical image analysis, was held in Vancouver, Canada. A total of 8 papers from Eagle Eye Technology Airdoc stood out and were finally included. One of them was presented at the conference as one of the few oral reports (Oral) papers, fully demonstrating the company's comprehensive and outstanding innovation capabilities in the field of medical artificial intelligence. What is MICCAI? The full name of MICCAI is the International Conference on Medical Image Computation and Computer-Aided Intervention (International Confere)
Eagle Eye Technology-B subscribes for $10 million to invest in Yonglong Wealth Management products
Eagle Eye Technology-B (02251) announced that on January 11, 2023, the company subscribed to CMB Wing Lung Wealth Management products provided by China Merchants Wing Lung Asset Management. The principal amount was 10 million US dollars. The announcement stated that the company believes that reasonable and proper financial management with low risk is conducive to improving the Group's capital utilization rate and increasing the income from temporarily idle funds, and is in line with the company's core goal of ensuring capital safety and liquidity.
AIRDOC-B: 2023 INTERIM REPORT
Hong Kong Stock Announcement Nuggets | Technology export revenue is growing rapidly, and monetization capacity has increased dramatically
Zhongan Online (06060) announced its interim results for the six months ended June 30, 2023. The group achieved insurance service revenue of RMB 12.692 billion, an increase of 23.84% over the previous year.
Analysis
Price Target
No Data
